Deal Team

Corporate
Finance
Tax
Antitrust
Executive Compensation and Benefits
Intellectual Property

Mallinckrodt plc in the $925 million sale of its Therakos business to CVC Capital Partners

On August 5, 2024, Mallinckrodt plc, a global specialty pharmaceutical company, and CVC Capital Partners, one of the world’s leading investment firms, announced that they have entered into a definitive agreement under which CVC will acquire Mallinckrodt’s Therakos business for a purchase price of $925 million, subject to customary adjustments.

Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Mallinckrodt.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.